Novartis announced positive new data from a Phase III trial evaluating the efficacy and safety of Cosentyx (secukinumab) in non-radiographic axial spondyloarthritis.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The FDA greenlit GlaxoSmithKline’s Nucala (mepolizumab) for treating severe eosinophilic asthma in children as young as 6 years.
GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and the company’s transglutaminase 2 small molecule program for celiac disease.
Biogen Inc. announced new data to support the consistent, long-term benefits of treatment with Tecfidera (dimethyl fumarate) over 10 years, as well as additional diroximel fumarate data that further characterize the tolerability profile of this investigational oral fumarate for relapsing multiple sclerosis.
An experimental Amgen Inc. drug that targets a specific genetic mutation reduced tumor size in around half of advanced lung cancer patients given the highest dose in a small, early-stage trial.
Ardelyx’s Phase III AMPLIFY study of tenapanor achieved the clinical trial’s primary endpoint, as well as all key secondary endpoints, in treating patients with chronic kidney disease (CKD).
AstraZeneca reported positive results from clinical trial programs for Brilinta and Farxiga, causing stock to jump 3.4 percent.
In a late-stage study, Genentech’s flu drug Xofluza showed significant efficacy as a preventative treatment.
Roche Holding’s Tecentriq drug combined with platinum-based chemotherapy reduced the risk of the disease worsening or death in patients with advanced bladder cancer.
The U.S. Food and Drug Administration approved the anti-PD-1 therapy Keytruda as a monotherapy for patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 with disease progression after one or more previous lines of systemic therapy.